CRMD - CorMedix receives notice of allowance for US patent application covering lead product DefenCath

2023-05-01 12:20:21 ET

• CorMedix ( NASDAQ: CRMD ) said it had received United States Patent and Trademark Office (USPTO) allowance for its patent claims on a catheter lock solution that can prevent infection and reduced blood flow in central venous catheters.
• CorMedix receives US patent for DefenCath and plans to resubmit NDA to FDA by mid-May.
• CorMedix’s newly allowed US patent application complements its existing licensed patent and could extend the patent protection for DefenCath until 2042.
• If approved by the FDA, DefenCath could also receive 10.5 years of marketing exclusivity in the US, including 5 years for New Chemical Entity designation, 5 years for Qualified Infectious Disease Product designation, and 6 months for a pediatric hemodialysis clinical trial post-approval .
• ( CRMD ) is trading 1% higher .

For further details see: